CN112402808A - Parasite inactivation device - Google Patents
Parasite inactivation device Download PDFInfo
- Publication number
- CN112402808A CN112402808A CN202011299673.3A CN202011299673A CN112402808A CN 112402808 A CN112402808 A CN 112402808A CN 202011299673 A CN202011299673 A CN 202011299673A CN 112402808 A CN112402808 A CN 112402808A
- Authority
- CN
- China
- Prior art keywords
- light source
- source generator
- handle
- tinea
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000045947 parasite Species 0.000 title claims abstract description 46
- 230000002779 inactivation Effects 0.000 title claims abstract description 23
- 230000000007 visual effect Effects 0.000 claims abstract description 15
- 230000001681 protective effect Effects 0.000 claims abstract description 14
- 210000001503 joint Anatomy 0.000 claims description 33
- 239000011324 bead Substances 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 10
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract description 7
- 238000001914 filtration Methods 0.000 abstract description 5
- 241000607479 Yersinia pestis Species 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 64
- 208000002474 Tinea Diseases 0.000 description 63
- 201000010099 disease Diseases 0.000 description 63
- 241000130764 Tinea Species 0.000 description 39
- 210000004209 hair Anatomy 0.000 description 31
- 241000233866 Fungi Species 0.000 description 30
- 206010037844 rash Diseases 0.000 description 28
- 210000000282 nail Anatomy 0.000 description 25
- 230000003902 lesion Effects 0.000 description 24
- 208000010201 Exanthema Diseases 0.000 description 23
- 201000005884 exanthem Diseases 0.000 description 23
- 239000003814 drug Substances 0.000 description 20
- 201000004647 tinea pedis Diseases 0.000 description 19
- 241000223238 Trichophyton Species 0.000 description 17
- 208000010195 Onychomycosis Diseases 0.000 description 16
- 210000003128 head Anatomy 0.000 description 16
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 16
- 201000005882 tinea unguium Diseases 0.000 description 16
- 206010005913 Body tinea Diseases 0.000 description 14
- 238000005286 illumination Methods 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 201000003875 tinea corporis Diseases 0.000 description 14
- 208000003251 Pruritus Diseases 0.000 description 13
- 201000010618 Tinea cruris Diseases 0.000 description 13
- 201000009862 superficial mycosis Diseases 0.000 description 12
- 241001480043 Arthrodermataceae Species 0.000 description 11
- 230000037304 dermatophytes Effects 0.000 description 11
- 230000002538 fungal effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 206010043866 Tinea capitis Diseases 0.000 description 10
- 241000893966 Trichophyton verrucosum Species 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000002674 ointment Substances 0.000 description 10
- 230000003071 parasitic effect Effects 0.000 description 10
- 206010040882 skin lesion Diseases 0.000 description 10
- 231100000444 skin lesion Toxicity 0.000 description 10
- 210000003371 toe Anatomy 0.000 description 10
- 206010039509 Scab Diseases 0.000 description 9
- 208000007712 Tinea Versicolor Diseases 0.000 description 9
- 206010056131 Tinea versicolour Diseases 0.000 description 9
- 230000007803 itching Effects 0.000 description 9
- 208000017520 skin disease Diseases 0.000 description 9
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000003628 erosive effect Effects 0.000 description 8
- 244000053095 fungal pathogen Species 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 229960004125 ketoconazole Drugs 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000004681 Psoriasis Diseases 0.000 description 7
- 229940121375 antifungal agent Drugs 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 210000004761 scalp Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 6
- 241000243190 Microsporidia Species 0.000 description 6
- 206010067197 Tinea manuum Diseases 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 206010033733 Papule Diseases 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000186427 Cutibacterium acnes Species 0.000 description 4
- 241001480036 Epidermophyton floccosum Species 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- 241000223229 Trichophyton rubrum Species 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 229940055019 propionibacterium acne Drugs 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 241000894007 species Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- 241000893976 Nannizzia gypsea Species 0.000 description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000005059 dormancy Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229960002509 miconazole Drugs 0.000 description 3
- 230000036211 photosensitivity Effects 0.000 description 3
- 201000011414 pompholyx Diseases 0.000 description 3
- 150000004032 porphyrins Chemical group 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241001124076 Aphididae Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- 206010034016 Paronychia Diseases 0.000 description 2
- 241000029132 Paronychia Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 241000237848 Sipunculus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229960003913 econazole Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 206010035114 pityriasis rosea Diseases 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000239267 Arguloida Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001062954 Clinopodium Species 0.000 description 1
- 241001563035 Clinopodium polycephalum Species 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 241001128004 Demodex Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 206010019049 Hair texture abnormal Diseases 0.000 description 1
- 241000248482 Ichthyophthirius multifiliis Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- BIXJFIJYBLJTMK-UHFFFAOYSA-N Lysergol Natural products C1=CC(C2=CC(CO)CN(C2C2)C)=C3C2=CNC3=C1 BIXJFIJYBLJTMK-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000035450 Malformed Nails Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- OCLFPEICMULBBI-UHFFFAOYSA-N O1C=CC=C1.N1=NC=CC2=CC=CC=C12 Chemical compound O1C=CC=C1.N1=NC=CC2=CC=CC=C12 OCLFPEICMULBBI-UHFFFAOYSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000509427 Sarcoptes scabiei Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043871 Tinea nigra Diseases 0.000 description 1
- 241001439624 Trichina Species 0.000 description 1
- 241001500087 Trichodina Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 235000002098 Vicia faba var. major Nutrition 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000022338 anthrax infection Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000455 fourth toe Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036072 healthy nails Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- 239000010015 huanglian Substances 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960002358 iodine Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000035984 keratolysis Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- BIXJFIJYBLJTMK-MEBBXXQBSA-N lysergol Chemical compound C1=CC(C2=C[C@@H](CO)CN([C@@H]2C2)C)=C3C2=CNC3=C1 BIXJFIJYBLJTMK-MEBBXXQBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000431 third toe Anatomy 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229940118257 zinc undecylenate Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0632—Constructional aspects of the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0644—Handheld applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0654—Lamps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0664—Details
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a parasite inactivation device comprising: a base portion and a handle portion; one end of the lamp holder part is connected with one end of the handle part in a clamping way; the lamp head part is internally provided with a light source generator, the handle part is internally provided with a photoelectric control unit and a power supply, or the lamp head part is internally provided with a light source generator and a photoelectric control unit, and the handle part is internally provided with a power supply; the photoelectric control unit is detachably connected with the power supply; the photoelectric control unit is detachably connected with the light source generator and can control the light source generator to emit light; the light source generator is provided with a first light source generator and a second light source generator. The light source generator is matched with the visual protective cover for use, and the visual protective cover has a light filtering function and can see bacterial fluorescence through a light filtering effect. The device provided by the invention not only can detect parasites and germs on plants and vertebrates, but also can kill germs and pests on plants and vertebrates.
Description
Technical Field
The invention belongs to the technical field of medical instruments, and particularly relates to a parasite inactivating device.
Background
There are more than about 200 parasites of humans and animals, such as superficial fungi;
superficial mycoses are skin diseases caused by pathogenic fungi that parasitize keratin tissues, the pathogenic bacteria of which can be classified as:
firstly, dermatophyte: pathogenic fungi that parasitize the keratin tissue of the skin are collectively referred to as dermatophytes. The bacterium is subdivided into the following three genera according to the difference of invading tissues and the difference of culture characteristics:
(one) Trichophyton: invading the skin, hair and nails. The genus has been identified with 13 species that cause disease in humans. Common trichophyton fulvum, trichophyton rubrum, trichophyton clinopodium, trichophyton purpureum, trichophyton gypseum, etc.; they are characterized by a rod-shaped macromolecular spore with smooth walls.
(II) Sporosporium: attack hair and skin, and are most common in China, such as microsporidia ferruginea, microsporidia laniformis and the like; these cultures are characterized by spindle-shaped macromolecular spores with thorns on the walls. There are 8 types reported to cause disease in humans.
(III) Epidermophyton genus: invading the skin and nails. Only one species of Epidermophyton floccosum is responsible for the pathogenesis of human beings, and its culture shows pestle-like or pear-like macrospores.
The dermatophytes of the three genera can cause tissue reaction after infecting human body, and then the papule, blister, scale, broken hair, alopecia, deck change and the like can occur. According to the difference of the invasion sites, the clinical classification can be tinea capitis, tinea corporis, tinea cruris, tinea manus, tinea pedis and onychomycosis.
II, trichophyton hornerianum: the pathogenic fungi that parasitize the cuticle or hair shaft surface of the skin can be called trichophyton. The ringworm is divided into two types, namely horny layer type and hairline type. The former includes tinea versicolor, Microcorynebacterium erythraeum, Trichophyton mansoni and Trichophyton Venezans; the latter type has Trichophyton axillaris.
Since the fungus Trichophyton angustifolium is parasitic on the surface of human tissue, it generally does not cause inflammatory reaction of the tissue, and is very slight if any.
[ epidemiology ]
Superficial mycosis is very popular, is spread in all regions of the world and is a common frequently-occurring disease in China. The incidence of the skin diseases accounts for the second or third, some or even the first place of the total number of the patients out-patient department of dermatology according to the reports of several hospitals in Shanghai; according to the data of investigating the disease condition of the Yunnan Gui front line officers in 1985, the data of a certain team is as follows: 2370 officers and soldiers in a certain group army are subjected to physical examination by the hospital, and the result shows that 1414 people suffering from superficial mycosis account for 59.66% of the examined people; in the statistics of 40731 cases of primary clinic cost in 1964 with 1955-. Superficial mycosis occurs in connection with the type of species, the antibacterial power of an individual and the environment, but the skin diseases are prevalent and have high incidence, and the reason for this is probably related to the following factors:
the fungus has extremely strong viability: the strain does not contain chlorophyll and has no photosynthesis ability, and only depends on parasitism or saprophytosis for survival. The fungi prefer a moist and warm environment, the optimum growth temperature is 25-26 ℃, and the fungi can grow under the condition of the pH value of 3.0-10.0. Although weak against high temperature (above 45 ℃), it has strong adaptability to temperature below 4 ℃, and also has considerable resistance to ultraviolet rays, radioactive rays, etc. It follows that fungi are not critical to the living conditions. Therefore, people can culture and detect pathogenic fungi from the atmosphere, animal and plant bodies, human excrement, floors, soil and the like, in short, the fungi have extremely strong living capability and almost do not exist everywhere in the nature, so the opportunity of the fungi to infect human beings is naturally increased.
Secondly, the bacteria carriers are the main reason for epidemic propagation of superficial mycosis: because people do not know enough about the harmfulness of tinea, people do not pay attention to it and often have diseases to do its development. In terms of tinea pedis, most patients have a very mild and itching condition, so the patients do not seek medical attention actively; even if some patients have more obvious symptoms, the patients still cannot be treated actively, and are familiar with the symptoms due to long-term illness; some patients are cured after treatment, but the infection source is not controlled and no preventive measures are taken, so the patients are frequently relapsed. The three people exemplified above are carriers, which ultimately have consequences: tinea may be caused by autoinfection in other places; can be spread to the surrounding people through various ways for the society.
Thirdly, the spread of pathogenic fungi is so extensive that prevention is rather difficult: the spread of the disease is quite extensive, and pathogenic bacteria can be spread widely through public articles such as slippers, bathtubs, footbaths, towels, haircutting tools and the like. Therefore, the public places need strict management and disinfection measures, otherwise, the control of the disease incidence is not easy to realize.
Fourthly, the strength and weakness of the body resistance also have the effect of being not overlooked to the epidemic: although it is considered that the fungal infectivity is low, the disease is not easily developed even between toes if no wound is locally generated. But it is well known that people who are not personal hygiene are not concerned; patients with systemic diseases, such as diabetes, malignant tumor, etc.; for long-term use of corticosteroids, immunosuppressants and antibiotics. The above will certainly promote the occurrence of tinea.
Fifthly, the external environment also has an important relationship with the prevalence of tinea: fungi prefer to grow and reproduce in a humid environment, so the disease is easy to occur among toes and is frequently attacked or aggravated in a damp and hot area and in hot summer.
As can be seen from the above description, superficial mycosis is a disease with a certain infectivity, which can be either a self-infection or a contagious infection. The infection mode of the disease is as follows: once infected by direct contact, the onset of tinea capitis is often caused by direct contact with children suffering from tinea capitis or animals suffering from tinea; the second is indirect infection, for example, tinea may occur when the patient frequently uses the articles used by tinea such as slippers, pillow towels, foot-rubbing cloths, etc.
[ clinical types and symptoms ]
Tinea capitis (Tineascapis)
The disease is a superficial mycosis which occurs in the skin and hair of the head, and the tinea capitis is basically divided into four types in China, namely, yellow tinea, white tinea, black tinea and purulent tinea.
Tinea pedis
The pathogenic bacteria of tinea flavum are dermatophytes and Mongolian variants thereof. The morbid stage of the disease is called alopecia, and the disease is called glaucomatosis in south China, the disease is mainly popular in rural areas, and is mostly seen in children of 7-13 years old, and the ratio of male and female is 9: 1, but may also occur in adults and adolescents.
The disease occurs in the scalp, where the initial lesions are papules or pustules, and then dry, crusted and yellowish in color. Scabs can spread and enlarge, being as large as soybeans or larger. The scab has a similar appearance to a dish, and has a slightly raised periphery and a slightly depressed center with hairs penetrating through the scab, which is called a yellow ringworm composed of a group of yellow ringworm, sebum, scales, and dust. Is an important characteristic of psoriasis and is helpful for diagnosis. Meanwhile, the disease is also suggested to have strong infectivity, and isolation treatment is often needed. The scab like bean dregs is easy to be crushed and smells mouse smell, which is another characteristic of the disease. The adjacent scabs can fuse with each other to form a large gray yellow thick scab, and if the scab is scraped off, the scab can be flushed and wet or superficial to a sexual ulcer, if the hair follicle can be damaged without treatment, and the atrophic scars are left after healing.
The affected hair is dry, withered and bent, and has loose hair loss, but no broken hair is found. No matter how serious the patient suffers from the disease around the scalp, a normal hairband about 1 cm wide is still remained at the hairline, and the hair can not be affected at the hairline.
The psoriasis has itching and lingering course of disease, and cannot be self-healed until adults are treated if the psoriasis is not treated. Erosion and suppuration may be accompanied by swelling of the cervical lymph nodes. Except for the head, the face, neck, trunk and nails are occasionally involved. In severe cases, allergic reactions may also occur, and sometimes a rash occurs throughout the body, which is called tinea and fungus rash.
The disease can be detected by ultraviolet lamp irradiation, and the affected part shows dark green fluorescence, and the disease is detected by endoscopic extraction to obtain endophytic hyphae, and spore or antler-like hyphae can be detected by yellow tinea crust.
Tinea alba (II)
Tinea alba is mainly caused by infecting microsporum pucciniae in China. Is often popular in township centers or primary schools. Almost all are childhood onset.
Scalp lesions are scales and speckles, while small ones are like broad beans, large ones are like coins, and the scales spread and enlarged with time, and are mostly irregular in shape. The inflammatory reaction is not obvious in the lesion, but the boundary is clear. The disease is dry and the loss of luster is usually mainly caused by broken hair, which is different from tinea pedis. The hair is broken at a position 2-5 mm away from the scalp, and white fungus sheaths can be seen on the outer surface of the hair shaft of the affected part close to the scalp, and the hair is also formed by fungi and is considered as one of the characteristics of the disease.
The affected area can be irradiated by the filtered ultraviolet lamp to show bright green fluorescence. When the hair is examined by microscope, the appearance of the spore is determined, and when the fungus is examined by microscope at the early stage of picking the dandruff, the spore is always positive. 97% of the culture was microsporidia ferruginea, the rest being other microsporidia.
The patients feel itchy or have no obvious symptoms, the disease course is chronic, the patients can self-heal by the adolescence usually without treatment. This may be associated with vigorous sebum secretion and increased local free fatty acid concentration in young people to inhibit fungi. After the disease is cured, new hair can regenerate without leaving scar.
(III) tinea nigra
The pathogenic bacteria of the disease are purple trichophyton or trichophyton clinopodium polycephalum. Mainly invade children, and the incidence rate of the children is behind tinea alba and tinea flavum.
Head damage is similar to tinea alba and appears as scale plaque, but the lesion area is smaller and the number is more than that of tinea alba. In addition, the diseased hair is slightly different from tinea alba, mainly presents low-position broken hair, is usually broken at a position 1-2 mm away from the scalp, and even breaks when one scalp breaks. The affected part is observed to have only black residual hair roots, so the product is named as tinea versicolor.
The disease has no fluorescent appearance to the test of the filtered ultraviolet lamp. The disease is picked up and detected as endospore, and hypha can be detected in early dandruff. 80% of the cultured trichophyton purpureum is cultured, and 20% of the cultured trichophyton clinopodii is cultured.
The infectivity of this disease is weaker than that of yellow ringworm and white ringworm. Itching or no discomfort. The disease course is slow, a few scars are left after the recovery, and the hair part is bald.
(IV) tinea pedis
Tinea pedis is caused by infection with an animal-tropic fungus, such as microsporidia gypseum or microsporidia lanuginosus.
Most of the skin lesions are large and swollen like large-block-shaped carbuncles, the inflammatory reaction is severe, the hair follicles of the affected parts are suppurative, and pus can be squeezed out from the hair follicles. The hair at the diseased part is easy to break and fall, and the residual hair is very loose and is not easy to pull out. Scars are often left after recovery, and the fungus microscopic examination and culture are positive when the disease is cured.
The subjective symptoms of the disease usually indicate pain or itching. Swelling of the cervical lymph nodes is often accompanied. Some patients also have general symptoms such as fever, lassitude and inappetence.
Second, tinea corporis (Tineaccorporisis)
The skin diseases caused by dermatophytes infected by the smooth skin on the surface of the human body except the head, the palms and soles, the groin, the negative part and the nails are collectively called tinea corporis. Also named as Yuanxuan or jin Qian Xuan Ling. The common pathogenic bacteria of the disease are trichophyton rubrum, trichophyton gypseum, epidermophyton floccosum, trichophyton purpurea and the pathogenic bacteria of tinea capitis.
Tinea corporis is common to children and then teenagers. The clinical manifestations of this disease are related to the species of pathogenic fungi and individual reactions. The rash begins to become erythema or papule, and then the lesion gradually becomes telecentric and expands to the periphery, the center of the lesion tends to be self-healing, and the lesion becomes annular for a long time. The rim of the ring is slightly elevated compared to the adjacent normal skin where inflammation is more pronounced with small papules, blisters or scales attached. Sometimes, the rash may appear in the center of the ring, and the new skin lesion gradually expands into the ring, so that a plurality of concentric rings are formed in succession, which makes the border clear. The difference in the size and number of the skin lesions is also variable, with 1-2 or more lesions, the general occurrence of the disease is less common, and the distribution is also asymmetric. However, if the patient has an immunodeficiency or is chronically administered corticosteroids and immunosuppressants, the rash may appear to spread systemically.
In addition, the clinical common occurrence of the tinea corporis is called as atypical tinea corporis at present, which is caused by adopting corticoid cream to coat the lesion part by the self-advocate of patients who are misdiagnosed with other skin diseases or tinea corporis. After a period of treatment, the typical symptoms of the pathogenic tinea are destroyed, and instead, the inflammation reaction is severe, the lesion range is rapidly enlarged, the form is irregular, the boundary is not clear, and the tinea corporis is not easy to be identified, so the name is. This is due to the spread of pathogenic fungi caused by the decrease of local skin immunity after the use of corticosteroids. In this regard, it is difficult for an inexperienced physician to make a correct diagnosis.
Patients with tinea corporis have itching, and bacterial infection can occur after scratching. The scales around the lesions were scraped and microscopically examined to reveal hyphae or spores.
Tinea cruris (Tineacruris)
This disease can be considered as a special form of tinea corporis occurring on the medial aspect of the upper thigh. The pathogenic bacteria are common epidermophyton floccosum, and other dermatophytes can also cause diseases.
Tinea cruris is mostly male in adults and is rarely seen in women. Usually one-sided, also two-sided symmetrical distribution. In severe cases, the skin lesions can spread upward and directly reach the lower abdomen; spread backward to the buttocks; extending downward to involve elsewhere in the thigh.
The disease is different from tinea corporis in the following points: the tinea cruris damage form is rarely circular or elliptical, and is mostly irregular or arc; secondly, the tinea cruris skin lesion is often expressed as lichenification or acute and subacute eczematoid lesion; tinea cruris is easy to cause bacterial infection; the itching of tinea cruris is more severe.
Tinea cruris is generally caused by tinea pedis or tinea manuum infection, the disease condition is related to seasonal changes, and the tinea cruris usually recurs or aggravates in summer and can be relieved in winter. The course of the disease is lingering, and patients need to be treated with heart-fast treatment to recover, otherwise, the disease is easy to recur.
Tinea pedis and Tinea pedis (Tinea pidis)
The tinea pedis is the most common superficial fungus pathogen caused by foot infection by pathogenic fungi, and is called beriberi or damp among China folks. The main pathogenic bacteria of the disease comprise trichophyton rubrum, epidermophyton floccosum, trichophyton gypseum, trichophyton roseum and the like. In addition, the cause of Candida albicans is also frequently reported.
The tinea pedis is mainly caused by middle-aged and young-aged pathogenic bacteria. Children and older patients are less common, which may be associated with less activity and drier toes in these individuals.
The pathogenic bacteria can be easily found between the toes, especially in the third and fourth toe gaps. This is related to the close contact, wetness, stuffiness of the skin and poor evaporation of sweat from the above mentioned areas. The manifestations of tinea pedis skin damage are generally classified into the following three types:
(one) blister type: the deep blisters from the needle to the large millet are visible between the toes and on the sole, and the blister wall is thick and is scattered or densely distributed, so that the adjacent rashes can be fused to form a large blister. The bleb liquid is naturally absorbed and dried to be converted into scales.
(II) toe erosion type: it is commonly found in the space between the toes, and the affected area is damp and sweaty. The rash is initially soaked, and it is eventually accompanied by erosion, flushing and moistening due to pruritus or damage of epidermis after rubbing. It can cause the leakage of liquid to cause unpleasant odor.
(III) scale keratotic type: it is quite common to invade the sole, lateral foot, toe and heel. Skin damage is manifested as scaling, thickening of cutin, roughness and hardness, and chapping between skin, and the nature of the disease is particularly severe in winter.
The three types of skin lesions are often mixed and seen, but mainly one of them is called tinea pedis. For example, the blister type is marked by blisters, and erosion or scaling is observed in the meantime.
This disease is marked by the symptoms of itching, especially blister type and erosion between toes. The onset of tinea pedis is season dependent. It is usually mild in winter and heavy in summer. In summer, the skin becomes allergic to bacterial infection, which may cause ringworm and fever.
Tinea manuum (Tieea mauns)
Tinea manuum is a superficial mycosis occurring on the palm surface, and is similar to the "fungal infection of the hand" in traditional Chinese medicine. Can be primary, but most are transmitted from tinea pedis itself. The pathogenic bacteria are the same as tinea pedis, and the clinical manifestations are almost the same as tinea pedis. Because the hands are exposed and the ventilation is much better than that of the feet, no interphalangeal erosion type appears clinically, but only the blister type and the scale keratosis type are seen. The clinical occasional erosion appears, but is usually caused by candida infection, but not by dermatophyte.
Sixthly, onychomycosis (Tineauguium)
Onychomycosis is caused by infection of tinea unguium with dermatophytes, commonly known as onychomycosis; if the lesion on nail caused by non-dermatophytes is called onychomycosis. Both onychomycosis and onychomycosis have been frequently mixed.
Onychomycosis lesions begin at the distal end, lateral margin, or fold of the nail. Appearing as abnormal nail color and morphology. Almost grey white and tarnished; the thickness of the deck is obvious, and the surface is uneven. It is loose and crumbly, often with keratin and debris deposited beneath the nail. Sometimes, the deck may be separate from the nail bed. In addition, a special type, fungal onychomycosis, is seen clinically. This pattern appeared not to thicken, but only a punctate white turbidity developed on the nail surface, followed by gradual expansion to spread to the entire nail. Onychomycosis is slow in disease course and can be treated for a lifetime if it is not treated. Onychomycosis is characterized clinically by increased thickness of the nail plate, visible transverse furrows in the surface, and sometimes brown. There was still a shiny feel without the deposition of inferior keratin and debris common to onychomycosis. Meanwhile, paronychia is accompanied with red swelling around the nail, and pain and tenderness are felt. There is little liquid seepage in the paronychia but no suppuration. The pathogenic bacteria of the disease are candida or aspergillus, and the fungi culture is needed to confirm the pathogenic bacteria.
Seventhly, tinea versicolor (Tieeaverersicolor)
The tinea versicolor is named purple-white palatine wind in traditional Chinese medicine because purple spots and white spots exist alternately. In view of the fact that the skin rash is flaccid in summer, the skin rash is also commonly called as sweat stain. This disease is caused by tinea versicolor parasitic to the horny layer of the epidermis. The bacterium is lipophilicity, and the previous culture often fails, so that the successful culture is frequently reported in China. It has also been proposed that tinea versicolor should not fall within the fungal category from the standpoint of fungal classification. Then, the skin disease caused by it should not be called tinea, so it is recommended to change to pityriasis versicolor.
Tinea versicolor is commonly found in the neck and chest and back. Sometimes, the proximal end of the upper limb is also affected. The basic lesion is macula, as large as soybean. The new rash was yellow brown or tan, and the old lesion was off-white. The surface of the skin lesion is attached with trace bran-like scales, and adjacent skin diagnoses can be fused with each other to form a larger irregular focus. Generally, the patients have no subjective symptoms, and occasionally have itching feeling when sweating.
Eight, tinea fungus eruption (Dermatophytides)
The dermatophyte rash refers to a rash of the fungus or its products occurring in other parts of the human body from the primary focus of menstrual blood circulation, and is an allergic reaction. The following conditions must be provided for this disease: there is an active primary fungal lesion; finding a fungus negative in the lesion of the ringworm rash; the condition of the ringworm rash is improved until the disease is resolved along with the control of primary active fungus focus; positive ringworm test must be used, but negative results can be excluded to the diagnosis of ringworm rash.
Tinea and fungus eruption can be divided into general type and limited type. The former rash is lichen-like rash, i.e. symmetrical and disseminated papules appear on the whole body, which are consistent with hair follicles and are about from needle head to chestnut grain; the latter type is mostly manifested as a pompholyx-like eruption, and is characterized by the occurrence of scattered or clustered deep blisters on the palms and the soles of the fingers, which are of different sizes, and the blister walls are not easily broken, and a few blisters, such as those larger than soybeans, can develop into larger blisters.
The disease is hard to feel itchy, and is especially more obvious in limitation type. In addition, other types of eruptions such as erythema multiforme, erythema nodosum are rare.
[ DIAGNOSIS AND IDENTIFICATION ]
Superficial mycosis can be diagnosed easily according to the medical history and clinical manifestations. If necessary, the following auxiliary checks can be carried out:
firstly, fungus microscopic examination: selecting scales or diseased roots at the edge of the skin lesion. Put on a glass slide, add a drop of potassium hydroxide solution, and cover the slide. Then placed on an alcohol lamp and heated for a while to promote keratolysis. And finally, microscopic observation is carried out. A positive fungal test has a diagnostic effect, and a negative fungal test cannot exclude the diagnosis of tinea.
Secondly, fungus culture: the conventional culture medium is Sabourauad (Sabourauad) culture medium. Inoculating scales, hairs or vesicle membranes taken from the focus, and culturing in a thermostat at 25-30 ℃. Colony growth can be seen after about 5 days generally, and then strain identification can be carried out. If no colonies grow after three weeks of culture, culture negatives may be reported.
Thirdly, checking by filtering an ultraviolet lamp: the lamp, also known as wood, is a lamp in which ultraviolet light passes through a glass unit containing nickel oxide, some fungi are visible in the dark, and colored fluorescence is produced under the irradiation of a filtered ultraviolet lamp. Therefore, important reference can be provided for diagnosing superficial mycosis, particularly tinea capitis, clinically according to the existence of fluorescence and different colors. In addition, the lamp is also helpful for group inspection such as nursery.
Superficial mycoses have to be identified with numerous skin diseases, briefly described as follows:
first, tinea capitis should be distinguished from psoriasis, seborrheic dermatitis and alopecia areata. Psoriasis is common in adults and occurs less in children. Except for the pathological changes of the head, it is often affected by the extension of the trunk and limbs. The skin lesions are plaques, and thick silvery white scales are attached to the surfaces of the plaques. The hair at the lesion is in a brush pen shape, but the hair itself has no pathological changes, namely, broken hair, alopecia, dry hair, withered hair and bent hair and the like are not seen; seborrheic dermatitis is common in adults and is better at the eyebrow, nasolabial sulcus, beard, axilla, center of trunk and pubic mons. The rash is erythema, pimple, and greasy scale on the surface. No broken hair and extreme itching; alopecia areata is commonly called as ghost shaving head. Before the disease occurs, mental disorder exists, the diseased part presents in a circle-like alopecia, the boundary is clear, and the alopecia area has no inflammatory reaction and no scale. The subjective feeling of itch was not felt. The above dermatosis trichome tests were all negative.
Secondly, identifying tinea corporis, pityriasis rosea and psoriasis: pityriasis rosea occurs frequently in the proximal ends of the trunk and limbs, and the rash spreads and is distributed symmetrically, mainly manifested as erythema, lesion long axis balanced with dermatoglyph or rib, and chaffy scale attached to the surface. Negative fungus microscopic examination; psoriasis is usually aggravated in winter and remitted in summer. The remainder of the authentication is as described above.
And thirdly, tinea cruris should be identified mainly by neurodermatitis and chronic eczema. The negative results of the fungal tests of both the nervous rash and the chronic eczema show that the two diseases have no slightly higher damaged edge than the adjacent normal skin and have no phenomenon of heavy summer and light winter.
And fourthly, the tinea manus and pedis is identified by eczema and pompholyx. Eczema usually involves the dorsal aspect of the hand and foot and the extending sides of the toes, and is usually distributed symmetrically. Acute rash is polymorphic lesion, and chronic rash often has obvious infiltration, can be changed like moss, has dark red color and is generally clear in boundary; pompholyx is usually associated with hyperhidrosis, which is usually caused by the side of fingers and the edge of palm. The fungal tests of the above diseases are all negative.
[ TREATMENT ]
First, whole body treatment
Ketoconazole (mono): at present, the medicine is taken orally to replace griseofulvin. Ketoconazole is a synthetic broad-spectrum antifungal imidazole. The antifungal mechanism is that the synthesis of lysergol which is an important component of the fungal cell membrane is inhibited, so that the normal function of the fungal cell membrane is lost, the permeability of the membrane is increased, and finally, the fungi are denatured and even die. According to clinical practice, the medicine has good curative effect on superficial mycosis.
Indications are as follows: it is mainly used for treating tinea capitis, generalized tinea corporis, severe tinea cruris and onychomycosis.
Contraindications: the medicine is forbidden for pregnant and lactating women due to liver function disorder.
Dosage: adult, 200mg, 1 time/day. Weight of children is less than 20 kg, 50mg, 1
The times/day; 20-40 kg of 100mg of the compound, 1 time per day; more than 40 kg can be taken according to the dosage of adults.
(II) other imidazoles: the antifungal effect of Itraconazole (Itraconazole) is 5-10 times that of ketoconazole, and the minimum dose for treating dermatophyte is 100mg per day.
Second, local treatment
The superficial mycosis of hair or nail plate is not affected, and topical therapy can be used for treating superficial mycosis, but it needs to be durable and take long time to take medicine. Two groups of drugs are commonly used.
The general antifungal medicine for external use: more commonly, the compound is prepared into ointment, cream and tincture as required by salicylic acid, benzoic acid, tolnaftate, undecylenic acid, zinc undecylenate, sulfur, iodine and the like for clinical selection.
(II) specific broad-spectrum antifungal agents: currently, the largest group of the currently widely used medicines has a common imidazole ring, i.e., imidazoles such as sulconazole (Miconazole), Miconazole (Miconazole), oxime conazole (oxiconazole), econazole (econazole) ketoconazole (ketoconazole) Bifonazole, clotrimazole (chlorotritimidazole) and the like are often prepared into 1-2% cream for clinical application.
Specific treatment method for various superficial mycoses
Tinea capitis
China has summarized good experiences of a set of five-character therapy, namely taking (medicine), washing (hair), applying (medicine), managing (hair) and disinfecting (toxicity). In contrast to this experience, ketoconazole may be administered orally for 4 weeks at the above doses; the hair is washed daily during the treatment period; continuously applying proper antifungal ointment for 1-2 months; haircut once a week until the hair is cured; daily articles of patients, such as hats, towels, pillow towels, combs and the like, need to be disinfected regularly.
(II) tinea corporis, tinea cruris, tinea manus and pedis
It is believed that the local treatment of tinea would be effective, but different forms of tinea drugs are used according to different conditions and different manifestations of skin injury.
1. Infection should be controlled first when tinea occurs with infection.
2. When swelling and exudation of the lesion are obvious, 3% boric acid water or 0.02% furan cinnoline solution can be selected for wet application, and after swelling and exudation are reduced, an external medicine for effectively treating tinea is selected.
3. For erosion and slight exudation, Huanglian Lian Zi oxide oil should be applied externally for 2-3 days, and then proper tinea ointment should be replaced.
4. When the lesion is of scale keratosis type, the tinea treating ointment is in the form of ointment or cream.
5. If the damaged part has chap phenomenon, and the tincture is not applied externally, ointment or cream is still selected.
6. The rash is mainly erythema and pimple, and can be made into tincture, ointment or cream.
7. High concentration of keratin exfoliants is prohibited for skin lesions on the face, medial thigh, etc. to avoid irritation and dermatitis.
8. As long as the formulation is chosen without errors, the external use medicine should not be frequently changed for many principal and secondary tonics. Each tinea treating ointment should be used for at least one week.
9. For patients with intractable or extensive skin damage and difficult healing by local therapy, ketoconazole can be orally taken for 200mg for 1 time/day for 4 weeks.
(III) onychomycosis
The disease should be treated locally in principle, but the thick nail plate is not easy to permeate medicine, so the common method for treating tinea cannot be adopted. The nail plate should be removed as much as possible before topical application, and then antifungal agents should be applied. The general method is as follows:
the first nail scraping method comprises the following steps: scraping the brittle part of the diseased nail with a knife as much as possible every day, and then externally applying 5% iodine tincture, 30% glacial acetic acid or Weishi liquid for 1-2 times every day until the disease is cured.
(II) A dissolving method: firstly, the skin around the nail is protected by adhesive plaster, then 25-40% of urea ointment is coated on the nail plate, and finally, a plastic film is covered and fixed by the adhesive plaster. Changing the dressing once every 2 days, removing the nail plate with forceps when the nail plate is softened and has floating feeling, changing the dressing according to the conventional method every day, and externally applying the tinea ointment after the wound surface is healed until the nail grows out.
If the treatment fails or the number of the diseased nails is large by the method, ketoconazole can be taken orally, and the disease can be cured in about half a year as the dosage is the same as the dose.
(IV) tinea versicolor
The disease is easy to cure, but it also recurs frequently. The traditional medicine, such as 20-40% sodium thiosulfate solution and 2.5% selenium sulfide emulsion, can be used for external application, and in addition, the imidazole cream can also obtain satisfactory effects.
(V) tinea fungus eruption
The whole body treatment of the disease can be processed according to the treatment principle of allergic skin diseases; antifungal drugs are not required for local application, and particularly, strong-irritation tinea drugs are not used. The preparation can be applied topically with mild zinc oxide oil or wet-applied with 3% boric acid water. In addition, active tinea foci must be treated actively.
In conclusion, the process of killing the skin parasites is complex, the method and the drugs are diversified, pathogens are distinguished before treatment, and the cost is high. The parasites have dormant bodies, and the drugs are not absorbed during the dormancy period, so that relapse is caused.
Disclosure of Invention
Technical problem to be solved
In order to solve the problems in the prior art, the invention provides a parasite killing device, which not only can see germs and pests on plants and vertebrates, but also can assist in killing parasites and germs on the plants and the vertebrates, and has the advantages of low cost, environmental protection and remarkable effect in the whole process.
(II) technical scheme
In order to achieve the purpose, the invention adopts the main technical scheme that:
a parasite inactivation device comprising: a base portion and a handle portion;
one end of the lamp holder part is connected with one end of the handle part in a clamping way;
the lamp head part is internally provided with a light source generator, the handle part is internally provided with a photoelectric control unit and a power supply, or the lamp head part is internally provided with a light source generator and a photoelectric control unit, and the handle part is internally provided with a power supply;
the photoelectric control unit is detachably connected with the power supply;
the photoelectric control unit is detachably connected with the light source generator and can control the light source generator to emit light;
the light source generator is provided with a first light source generator and a second light source generator;
the first light source generator can emit light with the wave band comprising 253.7nm +/-10 nm wavelength;
the second light source generator is capable of emitting light in a wavelength band including 385nm to 450 nm.
Preferably, when the lamp head part is internally provided with the light source generator, and the handle part is internally provided with the photoelectric control unit and the power supply,
the power supply is a battery;
the light source generator further includes: lamp stand, first circuit board and first butt joint:
the first circuit board is arranged on the lamp holder and is electrically connected with the lamp holder;
the first circuit board is electrically connected with the first pair of connectors;
the lamp holder, the circuit board and the first butt joint are all arranged in a shell of the lamp holder part;
wherein the lamp holder is located on the shell at one end of the emission light source, and the first butt joint is located at the other end of the shell.
Preferably, the first light source generator and the second light source generator are both mounted on the lamp socket and electrically connected thereto;
the first light source generator comprises two LED lamp beads with 253.7nm +/-10 nm of emitted light wavelength;
the second light source generator comprises two LED lamp beads with the emission light wavelength of 385nm-450 nm.
Preferably, the handle portion further comprises: a handle housing;
the handle shell is of a hollow cylindrical structure;
the photoelectric control unit and the battery are arranged in the handle shell.
Preferably, the photoelectric control unit includes: the second circuit board, the control key assembly, the battery charging contact head and the second pair of joints;
the second circuit board is respectively connected with the control key assembly, the battery charging contact head and the second pair of joints.
Preferably, one end of the second pair of joints is in power supply connection with the battery, and the other end of the second pair of joints is provided with two spring type electrodes;
the second pair of joints are arranged at the end part of the handle shell;
the first pair of joints of the lamp holder part can be clamped into the handle shell and is in conductive connection with the two spring type electrodes on the second pair of joints.
Preferably, the ends of the second pair of joints are provided with concentric annular electrode contact surfaces;
the inner circle of the concentric ring electrode contact surface is a positive electrode, and the outer circle is a negative electrode.
Preferably, the battery charging contact is provided with two electrodes, is connected with the tail of the battery and is used for charging the battery;
the control key assembly is arranged on the outer wall of the handle shell;
the control key assembly includes: a start key and a stop key.
Preferably, the base part further comprises: a housing and a visual shield;
the light source generator is arranged in the shell;
one end of the shell is connected with the handle part, and the other end of the shell is provided with the visual protective cover;
the visual protective cover is made of ultraviolet and blue light filtering materials, and other light sources are reserved to pass through the visual protective cover.
The end part of the visual protective cover is provided with a sponge.
Preferably, the method further comprises the following steps: a light guide rod;
the light guide rod is connected with the light source generator;
the power supply includes: one or more of dry batteries, storage batteries and external power supplies.
(III) advantageous effects
The invention has the beneficial effects that: the parasite killing device provided by the invention not only can find germs and pests on plants and vertebrates, but also can assist in killing the parasites and germs on the plants and vertebrates, and the whole process has low cost, environmental protection and obvious effect.
Drawings
Fig. 1 is a schematic overall structure diagram of a parasite inactivating apparatus provided by the present invention;
fig. 2 is a schematic overall structure diagram of a parasite inactivating device provided by the present invention;
[ description of reference ]
1. A first light source generator; 2. a second light source generator; 3. a sponge; 4. a visual shield; 5. connecting and clamping positions; 6. a clamping position; 7. a start key; 8. a stop key; 9. a regulator; 10. direction indication; 11. a support frame.
Detailed Description
For the purpose of better explaining the present invention and to facilitate understanding, the present invention will be described in detail by way of specific embodiments with reference to the accompanying drawings.
As shown in fig. 1 and 2: the embodiment discloses a parasite inactivation device, including: a base portion and a handle portion.
One end of the lamp holder part is connected with one end of the handle part in a clamping way; the lamp head part is internally provided with a light source generator, the handle part is internally provided with a photoelectric control unit and a power supply, or the lamp head part is internally provided with a light source generator and a photoelectric control unit, and the handle part is internally provided with a power supply; the photoelectric control unit is detachably connected with the power supply; the photoelectric control unit is detachably connected with the light source generator and can control the light source generator to emit light.
Wherein, the light source generator is provided with a first light source generator 1 and a second light source generator 2; the first light source generator 1 is capable of emitting light in a wavelength band including 253.7nm ± 10 nm; the second light source generator 2 is capable of emitting light in a wavelength band including 385nm to 450 nm.
Specifically, in this embodiment, when the light source generator is disposed in the light head portion, and the photoelectric control unit and the power supply are disposed in the handle portion, the power supply is a battery; the light source generator further comprises: lamp stand, first circuit board and first butt joint: the first circuit board is arranged on the lamp holder and is electrically connected with the lamp holder, and the first circuit board is electrically connected with the first pair of connectors; the lamp holder, the circuit board and the first butt joint are all arranged in a shell of the lamp holder part; wherein the lamp holder is located on the shell at one end of the emission light source, and the first butt joint is located at the other end of the shell.
In the present embodiment, the first light source generator 1 and the second light source generator 2 are both mounted on the lamp socket and electrically connected to the lamp socket; the first light source generator 1 comprises two LED lamp beads with 253.7nm +/-10 nm of emitted light wavelength; the second light source generator 2 comprises two LED lamp beads with the emission light wavelength of 385nm-450 nm.
Specifically, in this embodiment, the handle portion further includes: a handle housing; the handle shell is of a hollow cylindrical structure; the photoelectric control unit and the battery are arranged in the handle shell. The photoelectric control unit includes: the second circuit board, the control key assembly, the battery charging contact head and the second pair of joints; the second circuit board is respectively connected with the control key assembly, the battery charging contact head and the second pair of joints. One end of the second pair of joints is in power supply connection with the battery, and the other end of the second pair of joints is provided with two spring type electrodes; the second pair of joints are arranged at the end part of the handle shell; the first pair of joints of the lamp holder part can be clamped into the handle shell and is in conductive connection with the two spring type electrodes on the second pair of joints.
Specifically, the end parts of the second pair of joints are provided with concentric annular electrode contact surfaces; the inner circle of the concentric ring electrode contact surface is a positive electrode, and the outer circle is a negative electrode. The battery charging contact is provided with two electrodes, is connected with the tail of the battery and is used for charging the battery; the control key assembly is arranged on the outer wall of the handle shell; the control key assembly includes: a start key 7 and a stop key 8.
Finally, it should be noted that: the lamp cap part further comprises: a housing and a visual shield 4; the light source generator is arranged in the shell; one end of the shell is connected with the handle part, and the other end of the shell is provided with the visual protective cover 4; the end part of the visual protective cover is provided with a sponge 3.
The parasite inactivation device provided in this embodiment further comprises: a light guide rod; the light guide rod is connected with the light source generator. The power supply includes: one or more of dry batteries, storage batteries and external power supplies.
It should be noted that: the using method is that the light source generated by the device provided by the embodiment is directly adopted to directly irradiate the affected area. In practical application, the illumination intensity is determined according to the thickness required to penetrate, the adjustment is carried out, the illumination is changed from weak to strong, and each layer is irradiated sufficiently as far as possible. The size of the illumination area of the light source is determined according to the size of the area of the lesion. The single time and the number of times of irradiation are designed according to the pathogen and the self condition of the host. The distance of light source contact is set according to the condition of the parasite and the host.
The parasites described in this example include: bacteria, viruses, fungi, spores and parasites.
The principle for the visual and light-activated parasite inactivation in this example is as follows:
1. biomolecules such as nucleic acids and proteins are the material basis of life;
2. the light with the wavelength of 253.7nm or more can be absorbed by pyrimidine and purine in nucleic acid of microorganisms, so that the nucleic acid is promoted to generate a plurality of photoproducts through a base dimerization mode, and the molecular structure of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) is damaged. When the molecular structure is disrupted, the nucleic acid is difficult to replicate, and even if replication is possible, it often has defects, causing death of microorganisms and micro-invertebrates.
3. Organisms are composed of cells, except for viruses, which are RNA structures.
4. The most basic characteristic of organisms is metabolism, and most of microbial proteins contain porphyrin rings, wherein coproporphyrin can be activated into high-energy unstable porphyrin by blue light (wavelength of more than or equal to 405 nm), and then is combined with triplet oxygen to form unstable singlet oxygen, and the triplet oxygen is combined with compounds on cell membranes to damage the cell membranes, so that the cells die. Under the same condition, the porphyrin can also generate fluorescence, and can be clearly seen under the action of filtering.
5. Blue light can also kill microorganisms and micro-invertebrates by affecting transmembrane ion influx and altering intracellular PH.
6. The total amount of cells of vertebrates and plants is far larger than that of parasites, the reproducible amount is far more than that of parasites, and the parasites of microorganisms and micro invertebrates can be safely and reliably solved by adopting artificial light.
Therefore, the artificial light source with the 200-280nm wave band is directed to the nucleic acid of the pathogen; the artificial light source with the wave band of 405nm-450nm aims at the oxidized protein photolyzed by pathogens.
In the embodiment, the shell of the base part is provided with a connecting clamp 5 of the base part, which can be connected with a perspective protective cover or a light guide rod, as shown in fig. 1; one end of the light source generator emits light, the other end of the light source generator is provided with a positive electrode and a negative electrode, the light source generator can be operated after being electrified, the end is connected with a battery through a quick connection design, a clamping position 6 is shown in figure 1, a switch is arranged on a handle part, a start key 7 is pressed down, the device is started and defaulted to be in a strong light mode, light reaches a required value instantly, meanwhile, the default working time of the device is 40 seconds, the device automatically stops working when the working time is up, a prompt tone is generated every 2 seconds during the working period, and if the required period is ended, a stop key 8 is pressed down, and the. If the start key is pressed for 5 seconds, the device is changed into a flash mode, the start key is pressed again, the device is started, the light reaches a required value instantly, meanwhile, the default working time of the device is 40 seconds, the device stops for 1 second every 2 seconds, namely, the light sounds a prompt tone every 2 seconds, stops for 1 second and lights for 2 seconds, and the operation is stopped after the default setting time is completed for 40 seconds. During which a stop key is pressed if necessary to terminate. If necessary, switch back to the highlight mode and press the start key for 5 seconds. One side of the handle part is connected with the light source generator, the other side is provided with a charging port and an illumination intensity adjuster 9 which is a circular ring, 4 gears of 800lx, 1200lx, 2200lx and 3200lx are arranged on the circular ring, and as shown in a direction indicator 10 in fig. 1, the circular ring can be adjusted by twisting to a fixed position.
As shown in fig. 2, a low sodium lamp with heat dissipation is installed at one end of the parasite inactivating device in the embodiment by a spiral interface, wherein 1 wavelength is 253.7nm ± 10 nm; wherein 2, the wavelength is 405nm +/-10 nm; the light source generator and the photoelectric control unit are both arranged in the lamp holder part, according to the position of the circuit component, a switch is arranged on the lamp holder part, the start key 7 is pressed, the device is started and is in a high light mode in a default mode, light reaches a required value instantly, meanwhile, the device has a working time of 200 seconds in a default mode, the device stops working automatically when the time is up, during the period, a prompt tone is generated every 2 seconds, and if the working time is up, the stop key 8 is pressed, and the working stops. If the start key is pressed for 5 seconds, the device is changed into a flash mode, the start key is pressed again, the device is started, the light reaches a required value instantly, meanwhile, the default working time of the device is 200 seconds, every 2 seconds is spaced in the period, the device stops for 1 second, namely, every 2 seconds the light is on, a prompt sound is sounded, the device stops for 1 second and then lights for 2 seconds, the operation is circulated, the default setting time is completed for 200 seconds, and the work is stopped. During which a stop key is pressed if necessary to terminate. If necessary, switch back to the highlight mode and press the start key for 5 seconds. The photoelectric control unit of the device and the power supply assembly are connected with the light source generator on one side, the charging port and the illumination intensity regulator 9 are arranged on the other side, the photoelectric control unit of the device is a circular ring, 4 gears including 3200lx, 5000lx, 12000lx and 20000lx are arranged on the circular ring, and the circular ring can be adjusted to a fixed position by twisting. The blower is embedded in the lamp head part and blows towards the lamp bulb, and the blower is started when the light source starts to work until the work stops. The other end of handle portion has fast interface, can connect support frame 11 or unmanned aerial vehicle.
Example 1
The experimental person is free of photosensitivity, and aims at killing pathogens of trichophyton rubrum, trichophyton mentagrophytes, trichophyton floccosum, filamentous fungi, yeast-like bacteria, yeasts, sporomycetes, fusarium and candida albicans which are parasitic in human onychomycosis, the device uses a rechargeable battery as a power supply, adopts a 10W power LED as an inlaid luminous element of a light source generator, simultaneously adopts a wave band of 253.7nm +/-10 nm and a wave band of two 385nm-450nm, has the illumination intensity of 2200lx, uses a shading element as a transparent protective cover, covers one large side of the protective cover in a diseased region, compresses sponge on the protective cover, prevents radiation leakage, opens a light source to obviously fluoresce bacteria, accurately finds the position of a parasitic source, irradiates 10 seconds of light at the same position, uses a flash mode, three times per day and 6 days later, and has no activity and no dormancy of the parasitic. The newly grown nails of experimenters are normal, and sick nails are gradually sheared off according to the newly grown nails, so that healthy nails can be obtained, which is a successful parasite killing case.
Example 2
The experimental person is free of photosensitivity, aiming at Propionibacterium Acnes (PA) parasitized on the human face, the equipment uses a rechargeable battery as a power supply, adopts a 10w power LED as an inlaid light-emitting piece of a light source generator, simultaneously generates a band I253.7 nm +/-10 nm and a band II 385nm-450nm, and has the illumination intensity of 800-. After the metabolism of the experimenter, no inflammation phenomenon occurs in the affected area 30 days after the irradiation is finished, and the facial health is obtained. This is a successful parasite inactivation case.
Example 3
The experimental person is free of photosensitivity, aiming at Propionibacterium Acnes (PA) parasitized on the human face, the equipment is connected with a fixed power supply, a 10w power LED is used as an inlaid light emitting piece of a light source generator, a band I253.7 nm +/-10 nm and a band II 385nm-450nm occur simultaneously, the illumination intensity is 800-. After the metabolism of the experimenter, no inflammation phenomenon occurs in the affected area 30 days after the irradiation is finished, and the facial health is obtained. This is a successful parasite inactivation case.
Example 4
The experimental house has no light allergy, and aims at subcutaneous parasitic scabies, itch mites and demodex of livestock, the equipment uses a rechargeable battery as a power supply, adopts a 10w power LED as an inlaid luminous element of a light source generator, simultaneously generates a first 253.7nm +/-10 nm wave band and a second 385nm-450nm wave band, has the illumination intensity of 800-. Healthy skin is obtained. This is a successful parasite inactivation case.
EXAMPLE 5
Aiming at cryptotrichum amabilis, trichina, trichodina, fish lice, ductus obliquus, ichthyophthirius multifiliis, sipunculus glaucosus and sipunculus siphonatus of fish, the equipment is connected with a fixed power supply, a 10w power LED is used as an embedded luminous element of a light source generator, the first 253.7nm +/-10 nm waveband and the second 385nm-450nm waveband are generated simultaneously, the illumination intensity is 2000lx, the shading element is used as a goggles, the light source is connected with a light guide rod because the fish is in water, other parts except the light guide rod are on the water surface, the bacterial fluorescence can be obviously seen by turning on the light source, the position of a parasite source can be accurately found, the parasite source is moved once every 30 seconds in the same position until the disease area is comprehensively irradiated for three times every day by matching with an antibody, and no active parasite and no dormancy exist in the irradiation area after. After two weeks healthy fish were obtained. This is a successful parasite inactivation case.
Example 6
Aiming at plant anthracnose, the equipment is connected with a solar charging battery, a low-sodium lamp is used as an inlaid light-emitting piece of a light source generator, a 253.7nm +/-10 nm waveband and a 385nm-450nm waveband are generated simultaneously, the illumination intensity is 20000lx, the light-shielding piece is used as goggles in operation, a use area can be separated by a light shielding plate, a support is used for the equipment to be fixed within a range of 1 m away from a plant, an intense light mode is used, the period of a disease high-incidence area can be repeated every day for 40-200 seconds every time, after one week, the diffusion of the anthracnose in the irradiation area is obviously slowed down, and the area of the anthrax infection is obviously. This is a successful parasite inactivation case.
Example 7
Aiming at pseudomonas, xanthomonas, agrobacterium, corynebacterium, erwinia and mycoplasma in a high-incidence stage of plant parasitic bacteria, the equipment is connected with a solar charging battery, a low sodium lamp is used as an embedded luminous element of a light source generator, a first waveband of 253.7nm +/-10 nm and a second waveband of 385nm-450nm occur simultaneously, the illumination intensity is 20000lx, the operation and use shading element is a goggles, a use area can be separated by a shading plate, an equipment use bracket is fixed in a range of 1 m away from a plant, a strong light mode is used, each time is 40-200 seconds, the high-incidence stage of diseases can be carried out for multiple times every day, and after one week, bacteria in the irradiation area can not cause agricultural damage. This is a successful parasite inactivation case.
Example 8
Aiming at parasitic aphids, white spiders and borers cubs of hot peppers, the device shown in the figure 2 is used, qualified goggles are selected as a main radiation protection tool, the lamp holder part is connected with the support frame which is a 4-meter long rod, so that a person is away from a light emitting opening by more than 2 meters, a strong light mode is selected, the illumination intensity is selected to be 20000lx, a light source is started, parasitic fluorescence, such as green fluorescence, can be obviously seen under the action of a wave band of two 385nm-450nm through the goggles, the operator holds the rod and sends the light source to a diseased region for irradiation, the sound is prompted for 15 times every 30 seconds, and after the parasitic aphids, the operator can listen to the prompting sound without seeing the light source. Under the irradiation of 253.7nm +/-10 nm wave band and 385-450 nm wave band and 20000lx illumination intensity, parasites and cubs die rapidly and worm eggs cannot escape.
The technical principles of the present invention have been described above in connection with specific embodiments, which are intended to explain the principles of the present invention and should not be construed as limiting the scope of the present invention in any way. Based on the explanations herein, those skilled in the art will be able to conceive of other embodiments of the present invention without inventive efforts, which shall fall within the scope of the present invention.
Claims (10)
1. A parasite inactivation device, comprising: a base portion and a handle portion;
one end of the lamp holder part is connected with one end of the handle part in a clamping way;
the lamp head part is internally provided with a light source generator, the handle part is internally provided with a photoelectric control unit and a power supply, or the lamp head part is internally provided with a light source generator and a photoelectric control unit, and the handle part is internally provided with a power supply;
the photoelectric control unit is detachably connected with the power supply;
the photoelectric control unit is detachably connected with the light source generator and can control the light source generator to emit light;
the light source generator is provided with a first light source generator and a second light source generator;
the first light source generator can emit light with the wave band comprising 253.7nm +/-10 nm wavelength;
the second light source generator is capable of emitting light in a wavelength band including 385nm to 450 nm.
2. A parasite inactivation device according to claim 1,
when the light source generator is arranged in the lamp holder part and the photoelectric control unit and the power supply are arranged in the handle part,
the power supply is a battery;
the light source generator further includes: lamp stand, first circuit board and first butt joint:
the first circuit board is arranged on the lamp holder and is electrically connected with the lamp holder;
the first circuit board is electrically connected with the first pair of connectors;
the lamp holder, the circuit board and the first butt joint are all arranged in a shell of the lamp holder part;
wherein the lamp holder is located on the shell at one end of the emission light source, and the first butt joint is located at the other end of the shell.
3. A parasite inactivation device according to claim 2,
the first light source generator and the second light source generator are both mounted on the lamp holder and electrically connected with the lamp holder;
the first light source generator comprises two LED lamp beads with 253.7nm +/-10 nm of emitted light wavelength;
the second light source generator comprises two LED lamp beads with the emission light wavelength of 385nm-450 nm.
4. A parasite inactivation device according to claim 2,
the handle portion further includes: a handle housing;
the handle shell is of a hollow cylindrical structure;
the photoelectric control unit and the battery are arranged in the handle shell.
5. A parasite inactivation device according to claim 4,
the photoelectric control unit includes: the second circuit board, the control key assembly, the battery charging contact head and the second pair of joints;
the second circuit board is respectively connected with the control key assembly, the battery charging contact head and the second pair of joints.
6. A parasite inactivation device according to claim 5,
one end of the second pair of joints is in power supply connection with the battery, and the other end of the second pair of joints is provided with two spring type electrodes;
the second pair of joints are arranged at the end part of the handle shell;
the first pair of joints of the lamp holder part can be clamped into the handle shell and is in conductive connection with the two spring type electrodes on the second pair of joints.
7. A parasite inactivation device according to claim 6,
the end parts of the second pair of joints are provided with concentric annular electrode contact surfaces;
the inner circle of the concentric ring electrode contact surface is a positive electrode, and the outer circle is a negative electrode.
8. A parasite inactivation device according to claim 6,
the battery charging contact is provided with two electrodes, is connected with the tail of the battery and is used for charging the battery;
the control key assembly is arranged on the outer wall of the handle shell;
the control key assembly includes: a start key and a stop key.
9. A parasite inactivation device according to claim 1,
the lamp cap part further comprises: a housing and a visual shield;
the light source generator is arranged in the shell;
one end of the shell is connected with the handle part, and the other end of the shell is provided with the visual protective cover;
the end part of the visual protective cover is provided with a sponge.
10. A parasite inactivation device according to claim 1,
further comprising: a light guide rod;
the light guide rod is connected with the light source generator;
the power supply includes: one or more of dry batteries, storage batteries and external power supplies.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011299673.3A CN112402808A (en) | 2020-11-18 | 2020-11-18 | Parasite inactivation device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011299673.3A CN112402808A (en) | 2020-11-18 | 2020-11-18 | Parasite inactivation device |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112402808A true CN112402808A (en) | 2021-02-26 |
Family
ID=74774137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011299673.3A Pending CN112402808A (en) | 2020-11-18 | 2020-11-18 | Parasite inactivation device |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112402808A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114304126A (en) * | 2021-03-30 | 2022-04-12 | 茂生生物科技保定有限公司 | Method for killing solenopsis invicta |
Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN2136638Y (en) * | 1992-09-14 | 1993-06-23 | 张晶 | Portable device for detecting and therapy of skin disease |
US20050065579A1 (en) * | 2003-08-18 | 2005-03-24 | Chen George C.C. | Portable infrared device |
US20050154381A1 (en) * | 2003-12-31 | 2005-07-14 | Altshuler Gregory B. | Dermatological treatment with visualization |
US20060235493A1 (en) * | 2005-04-14 | 2006-10-19 | Dotson Robert S | Ophthalmic phototherapy device and associated treatment method |
US20070038206A1 (en) * | 2004-12-09 | 2007-02-15 | Palomar Medical Technologies, Inc. | Photocosmetic device |
US20080147053A1 (en) * | 2006-12-15 | 2008-06-19 | Korea Electro Technology Research Institute | Apparatus and method for photodynamic diagnosis and therapy of skin diseases and light source system thereof |
KR20090120351A (en) * | 2008-05-19 | 2009-11-24 | 서경식 | LED bed for treating skin diseases |
US20090314308A1 (en) * | 2007-04-13 | 2009-12-24 | Kim Darrick S H L | Germicidal Floor, Germicidal Foot, And Hand Cleaning System |
CN202515649U (en) * | 2012-04-21 | 2012-11-07 | 马云 | Novel inspector for skin lesion of skin disease |
CN203139413U (en) * | 2013-03-22 | 2013-08-21 | 北京德麦特捷康科技发展有限公司 | Dermatopathy therapeutic instrument with combined light source |
CN203329203U (en) * | 2013-06-20 | 2013-12-11 | 中国科学院苏州生物医学工程技术研究所 | LED portable hair increasing device |
US20140135798A1 (en) * | 2012-11-13 | 2014-05-15 | Jonathan David | Light therapy skin device |
CN103893916A (en) * | 2014-03-26 | 2014-07-02 | 蓝卫 | LED treatment assisting device |
US20140303547A1 (en) * | 2013-03-01 | 2014-10-09 | Klox Technologies Inc. | Phototherapeutic device, method and use |
US20150112411A1 (en) * | 2013-10-18 | 2015-04-23 | Varaya Photoceuticals, Llc | High powered light emitting diode photobiology compositions, methods and systems |
CN104964186A (en) * | 2015-07-14 | 2015-10-07 | 江苏达伦电子股份有限公司 | LED bulb capable of dissipating heat actively |
CN105520806A (en) * | 2016-02-14 | 2016-04-27 | 王萌萌 | Handheld cross-linking therapeutic system for ophthalmological department |
CN205402339U (en) * | 2016-02-18 | 2016-07-27 | 苏州仓建城市照明有限公司 | Portable emergency light convenient to dismantle |
CN205690146U (en) * | 2016-06-15 | 2016-11-16 | 周贵英 | Multi-light source LED pocket lamp |
CN206572268U (en) * | 2017-01-24 | 2017-10-20 | 厦门蓝水电子有限公司 | A kind of convenient and practical multifunctional lamp |
CN207006036U (en) * | 2017-06-23 | 2018-02-13 | 宁波多泰自动门有限公司 | A kind of warning lamp with double working modes |
CN208061437U (en) * | 2018-05-04 | 2018-11-06 | 宁波博盾安防科技有限公司 | A kind of functional traffic police baton |
CN208283256U (en) * | 2018-04-28 | 2018-12-25 | 成都泰然科技有限公司 | Biological material finds instrument |
CN109125938A (en) * | 2018-06-27 | 2019-01-04 | 南京唯亮光电科技有限公司 | A kind of integral type beauty instrument |
US20190038914A1 (en) * | 2016-02-02 | 2019-02-07 | Ushio Denki Kabushiki Kaisha | Sterilization apparatus |
US20190046812A1 (en) * | 2017-08-09 | 2019-02-14 | Acuity Innovation And Design, Llc | Hand-held Treatment Device Using LED Light Sources with Interchangeable Emitters |
US20190111240A1 (en) * | 2016-11-28 | 2019-04-18 | The Jenex Corporation | Devices for applying a topical treatment |
CN109771828A (en) * | 2017-11-14 | 2019-05-21 | 西安发威电子科技有限公司 | The infrared skin physiotherapy equipment of hand-held |
CN109954219A (en) * | 2017-12-25 | 2019-07-02 | 托普瑞德(无锡)设计顾问有限公司 | A kind of beauty lamp for anti-acne |
US20190314502A1 (en) * | 2018-04-12 | 2019-10-17 | Purdue Research Foundation | Targeted antimicrobial photodynamic therapy |
CN111511409A (en) * | 2017-10-11 | 2020-08-07 | 香港科技大学 | Asynchronous intermittent illumination for rapid surface disinfection |
CN111773554A (en) * | 2020-07-31 | 2020-10-16 | 复旦大学 | A red and blue light acne mask based on flexible fiber optic fabric |
CN211925590U (en) * | 2020-05-26 | 2020-11-13 | 厦门海莱照明有限公司 | Portable ultraviolet germicidal lamp |
-
2020
- 2020-11-18 CN CN202011299673.3A patent/CN112402808A/en active Pending
Patent Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN2136638Y (en) * | 1992-09-14 | 1993-06-23 | 张晶 | Portable device for detecting and therapy of skin disease |
US20050065579A1 (en) * | 2003-08-18 | 2005-03-24 | Chen George C.C. | Portable infrared device |
US20050154381A1 (en) * | 2003-12-31 | 2005-07-14 | Altshuler Gregory B. | Dermatological treatment with visualization |
US20070038206A1 (en) * | 2004-12-09 | 2007-02-15 | Palomar Medical Technologies, Inc. | Photocosmetic device |
US20060235493A1 (en) * | 2005-04-14 | 2006-10-19 | Dotson Robert S | Ophthalmic phototherapy device and associated treatment method |
US20080147053A1 (en) * | 2006-12-15 | 2008-06-19 | Korea Electro Technology Research Institute | Apparatus and method for photodynamic diagnosis and therapy of skin diseases and light source system thereof |
US20090314308A1 (en) * | 2007-04-13 | 2009-12-24 | Kim Darrick S H L | Germicidal Floor, Germicidal Foot, And Hand Cleaning System |
KR20090120351A (en) * | 2008-05-19 | 2009-11-24 | 서경식 | LED bed for treating skin diseases |
CN202515649U (en) * | 2012-04-21 | 2012-11-07 | 马云 | Novel inspector for skin lesion of skin disease |
US20140135798A1 (en) * | 2012-11-13 | 2014-05-15 | Jonathan David | Light therapy skin device |
US20140303547A1 (en) * | 2013-03-01 | 2014-10-09 | Klox Technologies Inc. | Phototherapeutic device, method and use |
CN203139413U (en) * | 2013-03-22 | 2013-08-21 | 北京德麦特捷康科技发展有限公司 | Dermatopathy therapeutic instrument with combined light source |
CN203329203U (en) * | 2013-06-20 | 2013-12-11 | 中国科学院苏州生物医学工程技术研究所 | LED portable hair increasing device |
US20150112411A1 (en) * | 2013-10-18 | 2015-04-23 | Varaya Photoceuticals, Llc | High powered light emitting diode photobiology compositions, methods and systems |
CN103893916A (en) * | 2014-03-26 | 2014-07-02 | 蓝卫 | LED treatment assisting device |
CN104964186A (en) * | 2015-07-14 | 2015-10-07 | 江苏达伦电子股份有限公司 | LED bulb capable of dissipating heat actively |
US20190038914A1 (en) * | 2016-02-02 | 2019-02-07 | Ushio Denki Kabushiki Kaisha | Sterilization apparatus |
CN105520806A (en) * | 2016-02-14 | 2016-04-27 | 王萌萌 | Handheld cross-linking therapeutic system for ophthalmological department |
CN205402339U (en) * | 2016-02-18 | 2016-07-27 | 苏州仓建城市照明有限公司 | Portable emergency light convenient to dismantle |
CN205690146U (en) * | 2016-06-15 | 2016-11-16 | 周贵英 | Multi-light source LED pocket lamp |
US20190111240A1 (en) * | 2016-11-28 | 2019-04-18 | The Jenex Corporation | Devices for applying a topical treatment |
CN206572268U (en) * | 2017-01-24 | 2017-10-20 | 厦门蓝水电子有限公司 | A kind of convenient and practical multifunctional lamp |
CN207006036U (en) * | 2017-06-23 | 2018-02-13 | 宁波多泰自动门有限公司 | A kind of warning lamp with double working modes |
US20190046812A1 (en) * | 2017-08-09 | 2019-02-14 | Acuity Innovation And Design, Llc | Hand-held Treatment Device Using LED Light Sources with Interchangeable Emitters |
CN111511409A (en) * | 2017-10-11 | 2020-08-07 | 香港科技大学 | Asynchronous intermittent illumination for rapid surface disinfection |
CN109771828A (en) * | 2017-11-14 | 2019-05-21 | 西安发威电子科技有限公司 | The infrared skin physiotherapy equipment of hand-held |
CN109954219A (en) * | 2017-12-25 | 2019-07-02 | 托普瑞德(无锡)设计顾问有限公司 | A kind of beauty lamp for anti-acne |
US20190314502A1 (en) * | 2018-04-12 | 2019-10-17 | Purdue Research Foundation | Targeted antimicrobial photodynamic therapy |
CN208283256U (en) * | 2018-04-28 | 2018-12-25 | 成都泰然科技有限公司 | Biological material finds instrument |
CN208061437U (en) * | 2018-05-04 | 2018-11-06 | 宁波博盾安防科技有限公司 | A kind of functional traffic police baton |
CN109125938A (en) * | 2018-06-27 | 2019-01-04 | 南京唯亮光电科技有限公司 | A kind of integral type beauty instrument |
CN211925590U (en) * | 2020-05-26 | 2020-11-13 | 厦门海莱照明有限公司 | Portable ultraviolet germicidal lamp |
CN111773554A (en) * | 2020-07-31 | 2020-10-16 | 复旦大学 | A red and blue light acne mask based on flexible fiber optic fabric |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114304126A (en) * | 2021-03-30 | 2022-04-12 | 茂生生物科技保定有限公司 | Method for killing solenopsis invicta |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7837719B2 (en) | Electrical stimulation unit and waterbath system | |
CN104306358B (en) | Antipruritic scar liniment of dispelling | |
CN112402808A (en) | Parasite inactivation device | |
Sharma et al. | Wolf's isotopic response: herpes simplex appearing on scrofuloderma scar. | |
RU2369415C1 (en) | Method of superficial burn treatment applied to children | |
CN105998021B (en) | The application of neferine prevention and treatment skin photoage | |
Gupta et al. | Textbook of dermatology for homoeopaths | |
Dembskey et al. | Laser therapy for the treatment of onychomycosis: best evidence based practice or not | |
Strickler et al. | Modern interpretation of mycotic infections of the feet and hands | |
Wrong et al. | Griseofulvin in the treatment of superficial fungous infections | |
Sharma et al. | Overview of Treating Skin Diseases and Rejuvenating Skin using Light Sources | |
RU2689026C1 (en) | Method of non-invasive treatment of plantar warts | |
Lee et al. | Current therapeutic insights regarding problematic fingernails and toenails in the Republic of Korea | |
Shamali | Development of a new approach (“Myc-PDI”) for the treatment of onychomycosis | |
Jackson et al. | CPD: Supporting your practice: Onychomycosis: A common and potentially significant medical condition | |
Pradhan et al. | Overview of Treating Skin Diseases and Rejuvenating Skin using Light Sources | |
KR20240014006A (en) | Method of preparing coin shape antibacterial composite and the composite thereby | |
Wairagade et al. | MANAGEMENT OF DADRU KUSHTA (FUNGAL INFECTION) IN AYURVEDA-A REVIEW ARTICLE | |
Pandya et al. | The effects of topically applied constituents of green tea (caffeine or (−)-epigallocatechin; EGCG) on UV-induced increase in p53 and apoptotic markers in the skin of human volunteers, a pilot study1 | |
CN110201033A (en) | A kind of drug and its preparation method and application for killing deep cortex fungi | |
CN113332399A (en) | Traditional Chinese medicine for treating chronic prostatitis and killing deep cortex fungi | |
Neves et al. | Photodynamic therapy for treatment of multiple lesions on the scalp in nevoid basal cell carcinoma syndrome: case report | |
Ahmad | Evaluation of Long Pulsed-ND: Yag Laser in The Treatment of Onychomycosis | |
Debta et al. | Efficacy of photodynamic therapy in the treatment of oral lichen planus by use of methylene blue | |
Malishevskaya et al. | To come in |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |